JP2016528299A - ビタミンｂ１２および内因子を含む組成物およびその使用方法 - Google Patents

ビタミンｂ１２および内因子を含む組成物およびその使用方法 Download PDF

Info

Publication number
JP2016528299A
JP2016528299A JP2016536494A JP2016536494A JP2016528299A JP 2016528299 A JP2016528299 A JP 2016528299A JP 2016536494 A JP2016536494 A JP 2016536494A JP 2016536494 A JP2016536494 A JP 2016536494A JP 2016528299 A JP2016528299 A JP 2016528299A
Authority
JP
Japan
Prior art keywords
tumor
composition
subject
cancer
atom
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2016536494A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016528299A5 (enExample
Inventor
ロバート・ドイル
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of JP2016528299A publication Critical patent/JP2016528299A/ja
Publication of JP2016528299A5 publication Critical patent/JP2016528299A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0497—Organic compounds conjugates with a carrier being an organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7135—Compounds containing heavy metals
    • A61K31/714—Cobalamins, e.g. cyanocobalamin, i.e. vitamin B12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
    • A61K47/551—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds one of the codrug's components being a vitamin, e.g. niacinamide, vitamin B3, cobalamin, vitamin B12, folate, vitamin A or retinoic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/0472—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
JP2016536494A 2013-08-22 2014-08-22 ビタミンｂ１２および内因子を含む組成物およびその使用方法 Pending JP2016528299A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361868841P 2013-08-22 2013-08-22
US61/868,841 2013-08-22
PCT/US2014/052381 WO2015027205A1 (en) 2013-08-22 2014-08-22 Compositions comprising vitamin b12 and intrinsic factor and methods of use thereof

Publications (2)

Publication Number Publication Date
JP2016528299A true JP2016528299A (ja) 2016-09-15
JP2016528299A5 JP2016528299A5 (enExample) 2017-09-28

Family

ID=52484208

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016536494A Pending JP2016528299A (ja) 2013-08-22 2014-08-22 ビタミンｂ１２および内因子を含む組成物およびその使用方法

Country Status (5)

Country Link
US (1) US20160199500A1 (enExample)
EP (1) EP3036008A4 (enExample)
JP (1) JP2016528299A (enExample)
CA (1) CA2921507A1 (enExample)
WO (1) WO2015027205A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6464166B2 (ja) 2013-11-14 2019-02-06 エンドサイト・インコーポレイテッドＥｎｄｏｃｙｔｅ， Ｉｎｃ． 陽電子放出断層撮影用の化合物
US20180154007A1 (en) * 2015-05-20 2018-06-07 Syracuse University Glycemic Control Using Intrinsic Factor Bound to A Vitamin B12 Conjugate of a Glucagon-Like Peptide-1 Receptor Agonist
CA3097381A1 (en) 2018-04-17 2019-10-24 Endocyte, Inc. Methods of treating cancer
WO2020113130A1 (en) * 2018-11-29 2020-06-04 The Trustees Of Dartmouth College Tumor targeting vitamin b12 derivatives for x-ray activated chemotherapy
EP3972432A4 (en) * 2019-05-20 2023-07-05 Syracuse University Pharmaceutical formulations and methods for delivering a therapeutic, diagnostic, or imaging agent to cd206
CN120097930A (zh) 2019-05-20 2025-06-06 因多塞特股份有限公司 制备psma缀合物的方法
WO2025072713A1 (en) 2023-09-27 2025-04-03 Judo Bio, Inc. Polymyxins for delivery of agents to the kidney
WO2025072699A1 (en) 2023-09-27 2025-04-03 Judo Bio, Inc. Aminoglycosides for delivery of agents to the kidney
WO2025072672A2 (en) 2023-09-27 2025-04-03 Judo Bio, Inc. Slc6a19-targeting modulatory nucleic acid agents

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH09508141A (ja) * 1994-07-29 1997-08-19 アムジエン・インコーポレーテツド ビタミンｂ▲下１２▼とタンパク質との複合体
JP2005508332A (ja) * 2001-09-28 2005-03-31 メイオウ・フアウンデーシヨン・フオー・メデイカル・エジユケイシヨン・アンド・リサーチ 薬剤を送達するための、輸送タンパク質とコンジュゲートコバラミンとの同時投与
JP2005514335A (ja) * 2001-10-19 2005-05-19 トマス ジェファソン ユニバーシティ 腫瘍イメージング及び治療のためのｐａｃａｐ組成物及び方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB733875A (en) * 1951-12-20 1955-07-20 Organon Nv Process for the manufacture of therapeutically active preparations
AU2003298169A1 (en) * 2003-03-24 2004-10-18 Schering Ag Modulators of the megalin-mediated uptake of radiotherapeutics and/or radiodiagnostics into kidney cells and their use in therapy and diagnostics
RU2007128036A (ru) * 2004-12-23 2009-01-27 Пердью Рисерч Фаундейшн (Us) Способ получения изображения позитронно-эмиссионной томографией
JP2006350686A (ja) * 2005-06-16 2006-12-28 Seiko Epson Corp 命令セット・シミュレータ生成装置及びシミュレータ生成方法
US20110092416A1 (en) * 2007-03-05 2011-04-21 Robert Patrick Doyle Vitamine B12 - Peptide Conjugates for Oral Delivery
EP2131855A2 (en) * 2007-03-05 2009-12-16 Syracuse University A conjugate of insulin and vitamin b12 for oral delivery
US20140161813A1 (en) * 2012-12-12 2014-06-12 Bauer Research Foundation Methods for the diagnosis, treatment and monitoring of cancer

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH09508141A (ja) * 1994-07-29 1997-08-19 アムジエン・インコーポレーテツド ビタミンｂ▲下１２▼とタンパク質との複合体
JP2005508332A (ja) * 2001-09-28 2005-03-31 メイオウ・フアウンデーシヨン・フオー・メデイカル・エジユケイシヨン・アンド・リサーチ 薬剤を送達するための、輸送タンパク質とコンジュゲートコバラミンとの同時投与
JP2005514335A (ja) * 2001-10-19 2005-05-19 トマス ジェファソン ユニバーシティ 腫瘍イメージング及び治療のためのｐａｃａｐ組成物及び方法

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
THE JOURNAL OF BIOLOGICAL CHEMISTRY, 1997, VOL.272, NO.42, PP.26497-26504, JPN6018020698, ISSN: 0003947113 *

Also Published As

Publication number Publication date
EP3036008A4 (en) 2017-04-05
CA2921507A1 (en) 2015-02-26
WO2015027205A1 (en) 2015-02-26
US20160199500A1 (en) 2016-07-14
EP3036008A1 (en) 2016-06-29

Similar Documents

Publication Publication Date Title
JP7393485B2 (ja) 前立腺特異的膜抗原（ｐｓｍａ）の標識インヒビター、前立腺癌の治療のための画像化剤および薬剤としてのその使用
JP2016528299A (ja) ビタミンｂ１２および内因子を含む組成物およびその使用方法
US11020493B2 (en) Double-labeled probe for molecular imaging and use thereof
ES2769538T3 (es) Kit de predireccionamiento, método y agentes que se usan en éste
EP2506876B1 (en) J591 minibodies and cys-diabodies for targeting human prostate specific membrane antigen (psma) and methods for their use
CN102438656B (zh) 预靶向试剂盒、方法和其中使用的试剂
ES2788865T3 (es) Conjugados farmacéuticos de nanopartículas
US11559591B2 (en) Ultrasmall nanoparticles labeled with Zirconium-89 and methods thereof
US20210386875A1 (en) Compositions and methods for treatment and imaging using nanoparticles
BR112021008480A2 (pt) dendrímeros, composição, métodos para determinar se um indivíduo tem um câncer, para determinar a progressão de um câncer, para determinar uma terapia apropriada para um indivíduo e para determinar a eficácia de uma terapia contra o câncer, métodos de imagem de um câncer em um indivíduo e de tratamento de câncer, usos de um dendrímero, intermediário para a produção de um dendrímero, kit e processo para a produção de um dendrímero
US20230125881A1 (en) Novel polypeptides and uses thereof
US10449261B2 (en) Compositions targeting radiation-induced molecules and methods of use thereof
US20210121569A1 (en) Nanotherapeutic systems and methods using particle-driven photodynamic therapy (pdt)
US20220257805A1 (en) Pharmaceutical formulations and methods for delivering a therapeutic, diagnostic, or imaging agent to cd206
US10758612B2 (en) Antibodies to tumor associated complex N-glycans with terminal GlcNAcβ residues and methods of use thereof
WO2015031645A1 (en) Monoclonal antibodies to human 14-3-3 epsilon and human 14-3-3 epsilon sv
Wu et al. Preclinical development of a novel [68Ga] Ga-/[177Lu] Lu-labeled agent for PSMA-targeted imaging and therapy
US11795197B2 (en) Peptide compositions for immuno-oncology molecular imaging and targeted drug delivery
EP4480502A1 (en) Radioactive complex of anti-vegf antibody, and radiopharmaceutical
KR20230163487A (ko) 항egfr 항체의 방사성 복합체 및 방사성 의약
Shan 125I-Radioiodinated tyrosine-folate and tyrosine-click-folate

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170818

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20170818

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20180605

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20190108